STAAR Surgical Co

STAAR Surgical insider buying signals confidence amid leadership change; market wary as RSUs vest and competition heats up, watch earnings and approvals for turnaround.

Insider confidence, institutional backing, and a high‑margin implant line signal a potential turnaround for STAAR Surgical Co., amid declining share price and evolving reimbursement models.

STAAR Surgical insider buys reveal confidence amid volatility—insider shares, Broadwood purchases, and market implications.

Broadwood’s steady buying of STAAR Surgical shares signals confidence in its safe, FDA‑cleared EDOF lenses—backed by strong 88% success rates—and a projected $650 million U.S. cataract implant revenue in 2027–29, making STAAR a top contender for inv…

Broadwood’s surge in STAAR Surgical shares signals confidence as the company pivots back to high‑margin implantable lenses and glaucoma devices, leveraging FDA approvals and a robust safety record to drive future value.